Atlas FDA

Oncomine Dx Target Test

FDA premarket approval P160045/S012 · decided 2018-11-29

Approval details

PMA number
P160045
Supplement
S012
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Oncomine Dx Target Test
Generic name
Next generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Life Technologies Corporation
Date received
2018-11-13
Decision date
2018-11-29
Days to decision
16 days
Decision code
OK30
Product code
PQP
Advisory committee
Pathology
Expedited review
No
Location
Carlsbad, CA
Statement
Move the storage location of finished component materials.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel (K241806)Life Technologies Corporation2025-01-08
Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (K233453)Life Technologies Corporation2024-07-10
Applied Biosystems™ 3500 Dx Genetic Analyzer and Applied Biosystems™ 3500xL Dx Genetic Analyzer (K191030)Life Technologies Corporation2020-02-21
Ion PGM Dx System (K170299)Life Technologies Corporation2017-06-22
QUANTSTUDIO DX REAL-TIME PCR INSTRUMENT (K123955)Life Technologies Corporation2013-03-08
STEMPRO MSC SFM (K103302)Life Technologies Corporation2011-02-18
KNOCKOUT SR MEDIUM, KNOCKOUT SR XENOFREE MEDIUM MODEL 10828, 12618 (K100616)Life Technologies Corporation2010-05-20